Use of omalizumab in the treatment of hypocomplementemic urticarial vasculitis

Real-World Experience on Omalizumab Treatment for Patients with Normocomplementemic Urticarial Vasculitis

“…3 Experience with omalizumab, an anti-IgE monoclonal antibody, has been used for treating hypocomplementaemic urticarial vasculitis. [5][6][7][8] In three case reports, NUV patients revealed remarkable response to omalizumab. [9][10][11] A prospective, open-label proof-of-concept study in a single center show that patients with NUV can benefit from omalizumab treatment during 12-week follow-up.…”

Systemic vasculitis and headache

“…IgAV: SHARE [181]; CS [182]; RTX [183]; MMF [184,185] Hypocomplementic-C1q: FVSG [186]; omalizumab [187] Variable vessel vasculitis Cogan: CS [79] Behc ¸et: CS [188]; MM [189]; colchicine or anti-TNF-a [190,191] Single organ vasculitis IgG4-RD: CS, RTX [192] Vasculitis associated with connective tissue diseases SLE: CS [96], AC [102] RV: CS [113]; RTX [193,194]; infliximab [195,196]; and AZA or MTX [197] a Tocilizumab (TCZ), an IL-6 receptor alpha inhibitor received weekly or every other week, combined with a 26-week prednisone taper was superior to either 26-week or 52-week prednisone tapering plus placebo with regard to sustained CS-free remission in patients with GCA. However, longer follow-up is necessary to determine the durability of remission and safety of tocilizumab before recommending it as standard therapy for GCA.…”